TORONTO, Feb. 2 /CNW/ - Amorfix Life Sciences Ltd. reported today that it
has obtained an exclusive worldwide license to novel targets on Superoxide
Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the
neurological disease Amyotrophic Lateral Sclerosis (ALS). The company also
obtained an exclusive five-year option to acquire the intellectual property
and know how surrounding the licensed technology. The company will use these
novel targets to initiate its therapeutic program for neurodegenerative
diseases, beginning with ALS.
